Your browser does not support iframes.
Pharma Tech Outlook Magazine, an authoritative journal for technological biopharmaceutical developments, published a special edition editorial featuring Guy Hadari, SVP & CIO, Teva Pharmaceuticals.
“In parallel with the systemic organization, we launched a project aimed at assessing world trends in innovation and the connection between healthcare and technology.” “The healthcare industry is undergoing change,” explains Hadari. “The patient is becoming an informed consumer with numerous opportunities to ‘shop around.’ Therefore, as a pharma company that produces products, we must adopt technology capabilities for the benefit of business and offer solutions that go beyond chemical intervention.“An example of a solution is incorporating technology into devices to follow-up with patients, such as an inhaler for treating asthma and other respiratory problems. Adding a sensor to the inhaler will report real-time data to doctors and include information such as whether the patient does indeed take the mediations prescribed and how frequently. This allows the doctor to improve patients’ treatment or alert him or her to a deterioration that requires medical intervention.”At Teva, considerable resources are being invested in technology and they are locating biotech companies or researchers from academia in order to find the ‘next thing.’ “The ability to analyze huge amounts of information wisely will become a significant advantage,” says Hadari. “Our competitors will not necessarily hail from the same field. If we do not know how to employ forces, we will be at risk.
“The future direction of technology in pharma primarily lies with cooperation with all aspects of technology bodies, such as our venture with Philips to establish a technology incubator. We understand that the ecosystem is changing. We are learning how to manage cooperation correctly and how to build structured work. “Additionally, we are examining how to produce a platform on which we can transfer accumulated data from the said sensor and analyze it to gain valuable information. To this end, we are speaking with a variety of organizations such as Philips, IBM and Google.”Regarding Philips, it is necessary to also reference Sanara Ventures Ltd.– a joint investment platform of Teva and Philips in which Sanara will provide financing and support to Israeli companies for medical technology and medical devices at early stages of development, in the fields of digital medicine, disease management, follow-up and sensors, image-guided minimally invasive treatment, drug delivery and combinations of drugs and devices. Sanara’s strategy is to invest in a wide range of innovative medical technologies that will influence both medical systems and medical and disease situations in the health service world that has been undergoing dramatic change in the past years. At Sanara they assume that additional investment will be made by the end of the year, with emphasis on the prudent building of the companies in these early stages.
Read the full Pharma Tech Outlook article (page 25).